Viking Therapeutics高管出售超过30万股，导致季度亏损后股价下跌6.1%。 Viking Therapeutics executives sold over 300,000 shares, triggering a 6.1% stock drop after a quarterly loss.

2026年1月5日,维京治疗公司的高管包括首席执行官布莱恩·利安,首席运营官玛丽安娜·曼奇尼和董事马修·福尔共售出超过30万股股票,股价下跌6.1%,至32.26美元. On January 5, 2026, Viking Therapeutics executives including CEO Brian Lian, COO Marianna Mancini, and Director Matthew Foehr sold a combined total of over 300,000 shares, triggering a 6.1% drop in the stock to $33.26. 该公司在2025年10月报告每股每股每股季度损失0.81美元之后,在SEC档案中披露的销售量即为缺失的估计数。 The sales, disclosed in SEC filings, followed the company’s October 2025 report of a quarterly loss of $0.81 per share, missing estimates. 股票的市场上限为36.6亿美元,P/E比率为负值,协商一致的 " 收购 " 评级为 " 购买 " ,目标价格为87.14美元。 The stock has a market cap of $3.66 billion, a negative P/E ratio, and a consensus “Moderate Buy” rating with a target price of $87.14.